Long-term outcome results of the first tandem autotransplant trial for multiple myeloma

British Journal of Haematology

Volumn 135, Issue 2, 2006, Pages 158-164

  Barlogie, Bart ^a,b   Tricot, Guido J ^b   Van Rhee, Frits ^b   Angtuaco, Edguardo ^b   Walker, Ron ^b   Epstein, Joshua ^b   Shaughnessy, John D ^b   Jagannath, Sundar ^c   Bolejack, Vanessa ^d   Gurley, Jennifer ^b   Hoering, Antje ^d   Vesole, David ^c   Desikan, Raman ^e   Siegel, David ^f   Mehta, Jayesh ^g   Singhal, Seema ^g   Munshi, Nikhil C ^h   Dhodapkar, Madhav ⁱ   Jenkins, Bonnie ^b   Attal, Michel ^j   Harousseau, Jean Luc ^k   Crowley, John ^d   more..

^a University of Arkansas for Medical Sciences ^*  (United States)

^b UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^c ST VINCENT S COMPREHENSIVE CANCER CENTER   (United States)

^d Fred Hutchinson Cancer Research Center   (United States)

^e Arkansas Specialty Orthopaedics   (United States)

^f HACKENSACK UNIVERSITY MEDICAL CENTER   (United States)

^g NORTHWESTERN UNIVERSITY   (United States)

^h DANA FARBER CANCER INSTITUTE   (United States)

ⁱ ROCKEFELLER UNIVERSITY   (United States)

^j CHU PURPAN   (France)

^k HÔTEL DIEU   (France)

more..

Author keywords

High dose melphalan; Myeloma; Prognosis

Indexed keywords

C REACTIVE PROTEIN; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; LACTATE DEHYDROGENASE; MELPHALAN;

ADULT; AGED; ANEMIA; ARTICLE; AUTOTRANSPLANTATION; CANCER DIAGNOSIS; CANCER RELAPSE; CANCER SURVIVAL; CHROMOSOME ANALYSIS; CHROMOSOME DELETION 13; CLINICAL PROTOCOL; CONTROLLED STUDY; DIPLOIDY; DISEASE FREE SURVIVAL; DISEASE SEVERITY; DRUG MEGADOSE; FEMALE; FOLLOW UP; HUMAN; LACTATE DEHYDROGENASE BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SURVIVAL RATE; SURVIVAL TIME; TREATMENT OUTCOME;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DISEASE PROGRESSION; DRUG ADMINISTRATION SCHEDULE; EPIDEMIOLOGIC METHODS; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; MELPHALAN; MIDDLE AGED; MULTIPLE MYELOMA; PROGNOSIS; RECURRENCE; TREATMENT OUTCOME;

EID: 33748748536     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2006.06271.x     Document Type: Article

References (28)

1. Alexanian, R., Haut, A., Khan, A.U., Lane, M., McKelvey, E.M., Migliore, P.J., Stuckey, Jr, W.J. & Wilson, H.E. (1969) Treatment for multiple myeloma. Combination chemotherapy with different melphalan dose regimens. JAMA, 208, 1680-1685.
2. Attal, M., Harousseau, J.L., Facon, T., Guilhot, F., Doyen, C., Fuzibet, J.G., Monconduit, M., Hulin, C., Caillot, D., Bouabdallah, R., Voillat, L., Sotto, J.J., Grosbois, B, Bataille, R. & InterGroupe Francophone du Myelome (2003) Single versus double autologous stem-cell transplantation for multiple myeloma. New England Journal of Medicine, 349, 2495-2502.
3. Attal, M., Harousseau, J.L., Leyvraz, S., Doyen, C., Hulin, C., Benboubker, L., Agha, I.Y., Bourhis, J.H., Garderet, L., Sotto, J.J., Michallet, M., Renaud, M., Voillat, L., Berthou, C., Marit, G., Monconduit, M., Dumonté, C., Caillot, D., Mathiot, C. & Avet-Loiseau, H. (2005) Maintenance treatment with thalidomide after autologous transplantation for myeloma: final analysis of a prospective randomized study of the Intergroupe Francophone du Myelome. Blood, 106, 1148 (abstr).
4. Avet-Loiseau, H., Facon, T., Grosbois, B., Magrangeas, F., Rapp, M.J., Harousseau, J.L., Minvielle, S., Bataille, R.& Intergroupe Francophone du Myelome (2002) Oncogenesis of multiple myeloma: 14q32 and 13q chromosomal abnormalities are not randomly distributed, but correlate with natural history, immunological features, and clinical presentation. Blood, 99, 2185-2191.
5. Barlogie, B., Smith, L. & Alexanian, R. (1984) Effective treatment of advanced multiple myeloma refractory to alkylating agents. New England Journal of Medicine, 310, 1353-1356.
6. Barlogie, B., Hall, R., Zander, A., Dicke, K. & Alexanian, R. (1986) High-dose melphalan with autologous bone marrow transplantation for multiple myeloma. Blood, 67, 1298-1301.
7. Barlogie, B., Alexanian, R., Dicke, K.A., Zagars, G., Jagannath, S. & Horwitz, L. (1987) High-dose chemoradiotherapy and autologous bone marrow transplantation for resistant multiple myeloma. Blood, 70, 869-872.
8. Barlogie, B., Jagannath, S., Vesole, D.H., Naucke, S., Cheson, B., Mattox, S., Bracy, D., Salmon, S., Jacobson, J., Crowley, J. & Tricot, G. (1997) Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma. Blood, 89, 789-793.
9. Barlogie, B., Tricot, G., Anaissie, E., Shaughnessy, J., Rasmussen, E., van Rhee, F., Fassas, A., Zangari, M., Hollmig, K., Pineda-Roman, M., Lee, C., Talamo, G., Thertulien, R., Kiwan, E., Krishna, S., Fox, M. & Crowley, J. (2006) Thalidomide and hematopoietic-cell transplantation for multiple myeloma. New England Journal of Medicine, 354, 1021-1030.
10. Bergsagel, D.E., Sprague, C.C., Austin, C. & Griffith, K.M. (1962) Evaluation of new chemotherapeutic agents in the treatment of myeloma IV: phenylalanine mustard. Cancer Chemotherapy Reports, 2, 87-99.
11. Cox, D.R. (1972) Regression tables and life tables. Journal of the Royal Statistical Society: Series B, 34, 187-202.
12. Desikan, R., Barlogie, B., Sawyer, J., Ayers, D., Tricot, G., Badros, A., Zangari, M., Munshi, N.C., Anaissie, E., Spoon, D., Siegel, D., Jagannath, S., Vesole, D., Epstein, J., Shaughnessy, J., Fassas, A., Lim, S., Roberson, P. & Crowley, J. (2000) Results of high-dose therapy for 1000 patients with multiple myeloma: durable complete remissions and superior survival in the absence of chromosome 13 abnormalities. Blood, 95, 4008-4010.
13. Facon, T., Mary, J.Y., Hulin, C., Benboubker, L., Attal, M, Renaud, M., Harousseau, J.L., Pegourie, B., Guillerm, G., Chaleteix, C., Dib, M., Voillat, L., Maisonneuve, J., Troncy, J., Dorvaus, V., Monconduit, M., Martin, C., Casassus, P., Jaubert, J., Jardel, H., Kolb, B. & Bauters, F. (2005) Major superiority of melphalan-prednisone (MP) + thalidomide (THAL) over MP and autologous stem cell transplantation in the treatment of newly diagnosed elderly patients with multiple myeloma. Blood, 106, 780 (abstr).
14. Fermand, J.P., Chevret, S., Ravaud, P., Divine, M., Leblond, V., Dreyfus, F., Mariette, X. & Brouet, J.C. (1993) High-dose chemoradiotherapy and autologous blood stem cell transplantation in multiple myeloma: results of a phase II trial involving 63 patients. Blood, 82, 2005-2009.
15. Gianni, A.M., Siena, S., Bregni, M., Tarella, C., Stern, A.C., Pileri, A. & Bonadonna, G. (1989) Granulocyte-macrophage colony-stimulating factor to harvest circulating haemopoietic stem cells for autotransplantation. Lancet, 2, 580-585.
16. Gregory, W.M., Richards, M.A. & Malpas, J.S. (1992) Combination chemotherapy versus melphalan and prednisone in the treatment of multiple myeloma: an overview of published trials. Journal of Clinical Oncology, 10, 334-342.
17. Harousseau, J.L., Attal, M., Divine, M., Marit, G., Leblond, V., Stoppa, A.M., Bourhis, J.H., Cailoot, D., Boasson, M. & Abgrall, J.F. (1995) Autologous stem cell transplantation after first remission induction treatment in multiple myeloma: a report of the French Registry on autologous transplantation in multiple myeloma. Blood, 85, 3077-3085.
18. Kaplan, E.L. & Meier, P. (1958) Nonparametric estimation from incomplete observations. Journal of the American Statistical Association, 53, 457-481.
19. Mantel, N. (1966) Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemotherapy Reports, 50, 163-170.
20. Mateos, M.V., Hernandez, M., Mediavilla, J.D., Palomera, L., Moro, M.J., Hernández, J., Lahuerta, J.J., De la Rubia, J., Terol, M.J., Sureda, A., Bargay, J., Arriba, F., Alegre, A., Rivas, P., García-Laraña, J., Ribera, J.M., Carrera, D., Bladé, J., Prósper, F., Esseltine, D.L., van de Velde, H., Schenkein, D. & San Miguel, J.F. (2005) A phase I/II national, multi-center, open-label study of bortezomib plus melphalan and prednisone (V-MP) in elderly untreated multiple myeloma (MM) patients. Blood, 106, 786 (abstr).
21. McElwain, T.J. & Powles, R.L. (1983) High-dose intravenous melphalan for plasma-cell leukaemia and myeloma. Lancet, 2, 822-824.
22. Palumbo, A., Bringhen, S., Caravita, T., Merla, E., Capparella, V., Callea, V., Cangialosi, C., Grasso, M., Rossini, F., Galli, M., Catalano, L., Zamagni, E., Petrucci, M.T., De Stefano, V., Ceccarelli, M., Ambrosini, M.T., Avonto, I., Falco, P., Ciccone, G., Liberati, A.M., Musto, P., Boccadoro, M. & Italian Multiple Myeloma Network (2006) Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomized controlled trial. Lancet, 367, 825-831.
23. Rajkumar, S.V., Blood, E., Vesole, D., Fonseca, R., Greipp, P.R. & Eastern Cooperative Oncology Group (2006) Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group. Journal of Clinical Oncology, 24, 431-436.
24. Richardson, P.G., Schlossman, R.L., Weller, E., Hideshima, T., Mitsiades, C., Davies, F., LeBlanc, R., Catley, L.P., Doss, D., Kelly, K., McKenney, M., Mechlowicz, J., Freeman, A., Deocampo, R., Rich, R., Ryoo, J.J., Chauhan, D., Balinski, K., Zeldis, J. & Anderson, K.C. (2002) Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood, 100, 3063-3067.
25. Richardson, P.G., Barlogie, B., Berenson, J., Singhal, S., Jagannath, S., Irwin, D., Rajkumar, S.V., Srkalovic, G., Alsina, M., Alexanian, R., Siegel, D., Orlowski, R.Z., Kuter, D., Limentani, S.A., Lee, S., Hideshima, T., Esseltine, D.L., Kauffman, M., Adams, J., Schenkein, D.P. & Anderson, K.C. (2003) A phase 2 study of bortezomib in relapsed, refractory myeloma. New England Journal of Medicine, 348, 2609-2617.
26. Singhal, S., Mehta, J., Desikan, R., Ayers, D., Roberson, P., Eddlemon, P., Munshi, N., Anaissie, E., Wilson, C., Dhodapkar, M., Zeddis, J. & Barlogie, B. (1999) Antitumor activity of thalidomide in refractory multiple myeloma. New England Journal of Medicine, 34, 1565-1571.
27. Tricot, G., Barlogie, B., Jagannath, S., Bracy, D., Mattox, S., Vesole, D.H., Naucke, S. & Sawyer, J.R. (1995) Poor prognosis in multiple myeloma is associated only with partial or complete deletions of chromosome 13 or abnormalities involving 11q and not with other karyotype abnormalities. Blood, 86, 4250-4256.
28. Zhan, F., Hardin, A., Kordsmeier, B., Bumm, K., Zheng, M., Tian, E., Sanderson, R., Yang, Y., Wilson, C., Zangari, M., Anaissie, E., Morris, C., Muwalla, F., van Rhee, F., Fassas, A., Crowley, J., Tricot, G., Barlogie, B. & Shaughnessy, Jr, J. (2002) Global gene expression profiling of multiple myeloma monoclonal gammopathy of undetermined significance and normal bone marrow plasma cells. Blood, 99, 1745-1757.